ALX Oncology Holdings financials
$1.35−2.88%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.2M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.2M |
| Gross margin | — | — | — | — | — | 100.0% |
| Operating income | -$104.0M | -$142.5M | -$170.3M | -$127.4M | -$83.6M | -$43.7M |
| Net income | -$101.7M | -$134.8M | -$160.8M | -$123.5M | -$83.5M | -$50.9M |
| Net margin | — | — | — | — | — | −4309.8% |
| Diluted EPS | $-1.90 | $-2.58 | $-3.74 | $-3.03 | $-2.07 | $-2.76 |
| EBITDA | -$100.1M | -$141.6M | -$169.4M | -$127.1M | -$83.5M | -$43.5M |
| Operating cash flow | -$84.1M | -$121.9M | -$130.4M | -$89.2M | -$72.4M | -$38.3M |
| Free cash flow | -$84.4M | -$122.4M | -$131.6M | -$90.7M | -$73.0M | -$38.3M |
| Diluted shares | 53.7M | 52.2M | 43.0M | 40.7M | 40.3M | 18.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $16.4M | $17.6M | $22.4M | $48.8M | $363.7M | $434.2M |
| Short-term investments | $28.4M | $110.2M | $160.3M | $217.4M | — | — |
| Total debt | $9.7M | $9.9M | $9.6M | $9.4M | $0.00 | $0.00 |
| Total assets | $59.0M | $147.8M | $242.6M | $306.5M | $380.2M | $436.1M |
| Total liabilities | $33.1M | $34.2M | $52.8M | $43.0M | $17.1M | $6.2M |
| Shareholders' equity | $26.0M | $113.6M | $189.7M | $263.5M | $363.0M | $429.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology